natgillin/translations-raw huggingface dataset:
It showed a close temporal relationship and positive rechallenge and dechallenge which support a causal relationship Ganfort PF and Asthma and other asthma-related symptoms including dyspnea and wheezing.
See näitas tihedat ajutist seost ja kõrvaltoimete tekkimist ravi taasalustamisel ja nende kadumist ravi ärajätmisel, mis toetas põhjuslikku seost ravimi Ganfort PF ja astma ning muude astmaga seotud sümptomite (muu hulgas düspnoe ja hingeldamine) vahel.
It slows down the rate at which amprenavir is broken down, increasing the
See aeglustab amprenaviiri lagunemist, suurendades amprenaviiri sisaldust veres.
It slows down the rate at which indinavir is broken down, increasing the levels of indinavir in the blood.
See aeglustab indinaviiri lagunemist, suurendades indinaviiri sisaldust veres.
It slows down the rate at which saquinavir is broken down, increasing the levels of saquinavir in the blood.
See aeglustab sakvinaviiri lagunemist, suurendades sakvinaviiri sisaldust veres.
it still concentrate.
olla paigal; keskenduda.
It stimulates the ‘transient receptor potential vanilloid 1’ (TRPV1) receptor which is found in the nerves in the skin that detect pain.
See stimuleerib transientset retseptoripotentsiaali tekitavat vanilloidretseptor-1 (TRPV1), mida leidub valutundlikes nahanärvides.
It stops a chemical in the body (substance P) from binding to the NK1 receptors.
Ravim takistab organismi teatud kemikaali (P- aine) kinnitumist NK1-retseptoritele.
It stops a chemical in the body called ‘substance P’ from attaching to the NK1 receptors.
See takistab teatud keemilise aine (P-aine) seondumist organismis NK1-retseptoritega.
It stops about a quarter of the fat in your meals from being absorbed.
Ta takistab umbes veerandi seedetraktis oleva rasva imendumist.
It stops eggs being released straight away.
See takistab teie munarakkude õigeaegset vabanemist.
It suppresses the activity of ‘T cells’, immune system cells that can become involved in organ rejection.
See pärsib T-rakkude (immuunsüsteemi rakud, mis on seotud elundi äratõukereaktsiooniga) aktiivsust.
It takes 83 seconds to deliver the laser dose required to activate Visudyne.
Visudyne’i aktiveerimiseks vajaliku laseri annuse saamine kestab 83 sekundit.
It takes about 30 minutes to prepare the injection.
Süsti ettevalmistamiseks kulub umbes 30 minutit.
It therefore decided that Esbriet’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Komitee otsustas, et Esbrieti kasulikkus ületab sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
It therefore possesses the properties of a serotonin re-uptake inhibitor and a tricyclic antidepressant.
Seetõttu toimib ta serotoniini tagasihaarde inhibiitorina ja sarnaselt tritsüklilise antideprssandiga.
It took 5.6 months for the disease to get worse in patients taking Xeloda and cisplatin, and 5.0 months in patients receiving 5-FU and cisplatin.
Xeloda ja tsisplatiini kombinatsiooni kasutanud patsientidel kulus haiguse progresseerumiseni 5,6 kuud, 5-FU ja tsisplatiini kombinatsiooni kasutanud patsientidel 5,0 kuud.
It took longer for patients on Bondronat infusions or tablets to develop a new bone complication (50 to 76 weeks) than for patients on placebo (33 to 48 weeks).
Bondronati infusiooni või tablette kasutanud patsientidel tekkisid uued luutüsistused hiljem kui platseeborühma patsientidel (Bondronati korral 50–76 nädalaga, platseebo korral 33–48 nädalaga).
It treats tick infestations and prevents new infestations for up to three weeks.
Ravim hävitab ka puuke ja hoiab ära uue nakatumise kuni kolme nädala jooksul.
It uses the same amorphous aluminium hydroxyphosphate sulphate adjuvant as qHPV vaccine.
Selles kasutatakse sama adjuvanti kui qHPV vaktsiinis – amorfset alumiiniumhüdroksüfosfaatsulfaati.
It usually takes 12 to 16 weeks for Xolair to show a benefit.
Tavaliselt kulub Xolairi kasuliku toime ilmnemiseks 12–16 nädalat.
It was a randomized, double-blind, active controlled, two-treatment, crossover study, comparing Enzepi to standard pancreatic enzyme treatment during
See oli randomiseeritud, topeltpime, aktiivse kontrollrühmaga, kahe raviga ristuvuuring, milles võrreldi Enzepi kasutamist standardse pankreaseensüümraviga kahel raviperioodil.
It was also compared with placebo as an add-on to atenolol in 889 patients and as an add-on to amlodipine in 728 patients.
Corlentori võrreldi platseeboga lisamisel atenoloolile (889 patsiendil) ja lisamisel amlodipiinile (728 patsiendil).
It was also compared with placebo as an add-on to atenolol in 889 patients and as an add-on to amlodipine in 728 patients.
Ivabradine Anpharmi võrreldi platseeboga lisamisel atenoloolile (889 patsienti) ja lisamisel amlodipiinile (728 patsienti).
It was also compared with placebo as an add-on to atenolol in 889 patients and as an add-on to amlodipine in 728 patients.
Procoralani võrreldi platseeboga lisamisel atenoloolile (889 patsiendil) ja lisamisel amlodipiinile (728 patsiendil).
It was also decided to introduce to ibandronic acid the same measures taken for other bisphosphonates and denosumab.
Samuti otsustati ibandroonhappe puhul kasutusele võtta samad meetmed nagu teiste bisfosfonaatide ja denosumaabi puhul.
It was also effective in children when used with ribavirin, with 46% of the children having responded to treatment at the six-month follow up visit following a year’s treatment.
Lastel oli ravimi kasutamine koos ribaviriiniga efektiivne, sest kuus kuud pärast üheaastase ravi lõppu toimunud järelkontrolliks oli ravivastus tekkinud 46%-l lastest.
It was also independent of age, sex, body surface area, renal and hepatic function, diagnosis and severity of the illness.
See ei sõltunud ka vanusest, soost, keha pindalast, neeru- ja maksafunktsioonist, diagnoosist ega haiguse raskusastmest.
It was compared with placebo or entacapone (another medicine for Parkinson’s disease).
Ravimit võrreldi platseebo või entakapooniga (samuti Parkinsoni tõve ravim).
It was demonstrated that the use of a 0.2 micron in-line filter removes visible particles and does not result in an apparent loss of protein or activity.
0,2-mikronilise filtri kasutamise korral infusioonisüsteemis on tõestatud nähtavate osakeste eemaldamine, mis ei põhjusta ilmset valgukadu ja ravimi toime vähenemist.
It was demonstrated that the use of a 0.2 micron in-line filter removes visible particles and does not result in an apparent loss of protein or activity.
On tõestatud, et 0,2-mikronilise filtri kasutamine eemaldab nähtavad osakesed ja ei põhjusta ilmset valgukadu ega ravimi toime vähenemist
It was designed to evaluate the efficacy and safety of guanfacine (1, 2, 3, and 4 mg/day) when co-administered with long-acting psychostimulants (amphetamine, lisdexamphetamine, methylphenidate, dexmethylphenidate) in children and adolescents aged 6-17 years with a diagnosis of ADHD and a suboptimal, partial response to psychostimulants.
Uuringu eesmärk oli hinnata guanfatsiini (1, 2, 3 ja 4 mg ööpäevas) efektiivsust ja ohutust pikatoimeliste psühhostimulaatoritega (amfetamiini, lisdeksamfetamiini, metüülfenidaadi, deksmetüülfenidaadiga) koosmanustamisel aktiivsus- ja tähelepanuhäire diagnoosiga 6–17-aastastel lastel ja noorukitel, kelle ravivastus psühhostimulaatoritele oli suboptimaalne ja osaline.
It was found that the early initiation of treatment resulted in a further reduced risk for the development of hepatocellular carcinoma (13.5-fold when initiated prior to the age of 12 months).
Hepatotsellulaarse kartsinoomi tekke ohtu vähendab veelgi ravi varane alustamine (oht väheneb 13,5 korda, kui ravi alustatakse enne patsiendi saamist 12 kuu vanuseks).
It was later confirmed that benefit is limited only to patients with wild-type RAS tumours, rather than patients with mutant RAS tumours.
Hiljem kinnitati, et kasulik toime avaldub üksnes patsientidel, kelle kasvajas esineb muteerumata RAS-geen, mitte muteerunud RAS-geen.
It was managed during the clinical programme by monitoring laboratory values and the use of a pre-specified management algorithm (see sections 4.3 and 4.4).
Kliinilistes uuringutes kasutati hüperkaltseemiaga toimetulemiseks vere kaltsiumisisalduse jälgimist ning eeldefineeritud ravi algoritmi (vt lõik 4.3 ja 4.4).
It was more effective than placebo at preventing death due to disease of the heart or blood vessels or hospitalisation due to worsening heart failure: 24.5% (793 out of 3,241) of patients treated with Ivabradine Anpharm died or were hospitalised for the first time due to worsening heart failure, compared with 28.7% (937 out of 3,264) of patients treated with placebo.
Ivabradine Anpharm ennetas kardiovaskulaarset suremust või haiglaravi progresseerunud südamepuudulikkuse tõttu efektiivsemalt kui platseebo: patsiente, kes surid või said esmakordset haiglaravi progresseerunud südamepuudulikkuse tõttu, oli Ivabradine Anpharmiga ravitud patsientidest 24,5% (793 patsienti 3241st) ja platseebot saanud patsientidest 28,7% (937 patsienti 3264st).
It was not clearly dose dependent, but most responses were seen at doses of ≥ 200 mg.
Toime ei olnud selgelt annussõltuv, kuid enamikel juhtudel täheldati toimet annuses ≥ 200 mg.
It was not possible to detect a rise in antibodies against C. felis because of high levels of antibodies in the cats at the beginning of the study.
Bakteri C. felis vastaste antikehade sisalduse tõusu ei olnud võimalik kindlaks määrata, sest kasside antikehade sisaldus oli uuringu algul suur.
It was not possible to detect stavudine in cerebrospinal fluid until at least 2 hours after oral administration.
Tserebrospinaalvedelikus muutus stavudiini kontsentratsioon määratavaks alles 2 tundi pärast suukaudset manustamist.
It was noted that Asian subjects had 1.5 fold increased exposure to lurasidone compared to Caucasian subjects.
Asiaatidest uuringus osalejatel täheldati 1,5-kordselt tõusnud lurasidooni seerumikontsentratsiooni võrreldes europiidsest rassist uuringus osalejatega.
It was noted that hyponatremia has been observed with similar frequency in the ranolazine (0.09%) and placebo (0.12%) groups in a placebo controlled study.
Märgiti, et platseebokontrolliga uuringus täheldati hüponatreemiat sarnase esinemissagedusega nii ranolasiini- (0,09%) kui ka platseeborühmas (0,12%).
It was primarily designed as a pharmacokinetic study (see section 5.2).
See uuring oli algselt mõeldud kui farmakokineetiline uuring (vt lõik 5.2).
It was primarily designed as a pharmacokinetic study (see section 5.2).
See uuring oli mõeldud peamiselt farmakokineetiliste näitajate uurimiseks (vt lõik 5.2).
It weakly inhibits dopamine reuptake with no significant affinity for histaminergic, dopaminergic, cholinergic and adrenergic receptors.
inhibeerib vähesel määral dopamiini tagasihaaret ning omab mitteolulist afiinsust histaminergiliste, dopaminergiliste, kolinergiliste ja adrenergiliste retseptorite suhtes.
It will also continue ongoing studies to further analyse the benefit of Strensiq in children from 13 to 18 years of age.
Ühtlasi jätkab ettevõte käimasolevaid uuringuid, et analüüsida täiendavalt Strensiqi kasulikkust lastel vanuses 13–18 aastat.
It will also include information on when not to use Multaq, medicines that interact with Multaq, and the need to monitor the function of the liver, lung, heart and kidneys before and during treatment to help manage the risk of severe complications.
Teabekaardis on ka teave, millal Multaqit ei tohi kasutada, Multaqiga koostoimet omavate ravimite loetelu ning selles rõhutatakse vajadust jälgida maksa-, kopsu-, südame- ja neerufunktsioone enne ravi algust ja ravi ajal, et aidata ohjata raskete tüsistuste riski.
It will also provide an information pack for patients to explain the medicine’s side effects, remind them of the need for adequate calcium and vitamin D supplementation, and when patients should contact their doctor.
See sisaldab ka patsientide teabepaket, milles selgitatakse ravimi kõrvalnähte, rõhutatakse vajadust võtta kaltsiumi ja D-vitamiini ning antakse soovitusi arsti poole pöördumiseks.
It will also stop air going back into the pen and the needle clogging up.
Samuti väldib see õhu sisenemist pen- süstlisse ja nõela ummistumist.
It will also stop air going back into the pen and the needle clogging up.
Samuti väldib see õhu sisenemist pen- süstlisseja nõela ummistumist.
It will also stop air going back into the pen and the needle clogging up.
Samuti väldib see õhu sisenemist pen-süstlisse ja nõela ummistumist.
It will also stop air going back into the pen and the needle clogging up.
Samuti väldib see õhu sisenemist pen-süstlisseja nõela ummistumist.
It will also supply all doctors in each Member State who prescribe Tysabri with an educational pack that includes information on the safety of Tysabri, including information on which patients may be at a higher or lower risk of PML.
Tootja varustab iga liikmesriigi kõik Tysabrit määravad arstid teabepakmega, mis sisaldab Tysabri ohutusteavet (sealhulgas selle kohta, millistel patsientidel on suurem või väiksem progresseeruva multifokaalse leukoentsefalopaatia risk).
It will also supply cards for patients to ensure that all appropriate safety measures are taken by each patient.
Turustaja annab ka patsiendikaardid, millega tagatakse, et kõik patsiendid võtavad kõik vajalikud ohutusmeetmed.
It will also supply cards for patients to ensure that all appropriate safety measures have been taken by each patient.
Tootja annab ka patsiendikaardid, millega tagatakse, et kõik patsiendid võtavad kõik vajalikud ohutusmeetmed.
It will also supply cards for patients to ensure that all appropriate safety measures have been taken by each patient.
Tootja annab patsientidele ka ohutusmeetmete meeldetuletuskaardid.
It will be administered into a vein by a health care professional.
Ravimi manustab veeni meditsiinitöötaja.
It will be given slowly over a period of 1 hour.
Ravimit manustatakse aeglaselt 1 tunni jooksul.
It will be given to you as an infusion (a drip) into a vein (intravenously) over a period of 90 minutes.
Ravimit manustatakse teile infusioonina (tilgutiga) veeni (intravenoosselt) 90 minuti vältel.
It will be given to you as an infusion through a long thin tube which goes into a vein (a drip), or into a small medical appliance that is inserted under the skin (port-a-cath) if you (or your child) have one implanted.
Seda manustatakse teile infusioonina pika peene vooliku kaudu veeni (tilgutiga) või naha alla sisestatud väikesesse meditsiiniseadmesse(Port-a-Cath süsteemi), kui see on teile (või teie lapsele) paigaldatud.
It will be injected into a muscle.
See süstitakse lihasesse.
It will be stored, to be given to the patient as replacement stem cells if Strimvelis cannot be given or does not work (see ‘When Strimvelis treatment cannot be completed’ in section 2) the treatment sample, 4 to 5 days before.
Seda säilitatakse manustamiseks patsientidele asendustüvirakkudena juhul, kui Strimvelis’t ei saa manustada või see ei toimi (vt „Kui Strimvelis-ravi ei saa lõpuni viia“ lõigus 2)
It will be used to make the Strimvelis, by putting a new gene into the cells.
Seda kasutatakse Strimvelis’e valmistamiseks, viies rakkudesse uue geeni.
It will contain either 30, 60 or 120 sprays, depending on the pack size that has been prescribed for you.
See sisaldab 30, 60 või 120 annust sõltuvalt teile määratud pakendi suurusest.
It will focus on the potential for severe hepatic injury with Zinbryta, and will also include information about symptoms of liver injury and instructions about monthly liver function monitoring.
See keskendub Zinbryta kasutamisel esinevale raske maksakahjustuse võimalusele ja sisaldab ka teavet maksakahjustuse sümptomite kohta ja juhiseid maksafunktsiooni igakuiste jälgimiste kohta.
It will not protect against other infectious agents that can cause ear infections.
See ei kaitse muude nakkusetekitajate vastu, mis võivad kõrvainfektsioone põhjustada.
It will only be effective as long as you are using it.
Selle toime püsib vaid senikaua, kui te ravimit kasutate.
It will only be handled and given to you by people who are trained and qualif ied to use it safely.
Ravimi käsitsemine ja manustamine on lubatud inimestel, kes on saanud vastava väljaõppe ja oskavad seda ohutult kasutada.
It will only spray when it becomes liquid.
Pihustada saab ainult vedelat ravimit.
It will provide a letter and educational kits for healthcare workers and brochures for patients, detailing the steps that need to be taken for the medicine to be used safely.
Ravimi turustaja koostab tervishoiutöötajatele kirja ja teabematerjalid ning patsientidele voldikud, milles kirjeldatakse üksikasjalikult ravimi ohutut kasutamist.
It will provide a letter and educational kits for healthcare workers, and brochures for patients, explaining that the medicine is expected to be harmful to the unborn child and detailing the steps that need to be taken for the medicine to be used safely.
See hõlmab kirja ja õppekomplekte tervishoiutöötajatele ning brošüüre patsientidele, milles selgitatakse, et ravim on sündimata lapsele eeldatavalt kahjulik, ja kirjeldatakse üksikasjalikult samme, mis on vajalikud ravimi ohutuks kasutamiseks.
It will quickly dissolve with your saliva and can be swallowed.
Sülg lahustab selle kiiresti ja võimaldab alla neelata.
It will snap shut.
See sulgub klõpsuga.
It works best against cells which are multiplying quickly – such as cancer cells.
See toimib kõige paremini kiiresti paljunevate rakkude – näiteks vähirakkude vastu.
It works by attaching to beta 2 receptors that are found in the muscle cells of many organs and that cause the muscles to relax.
See kinnitub β2- retseptorite külge, mida leidub paljude elundite lihasrakkudes ja mis lõõgastavad lihaseid.
It works by attaching to beta-2 receptors found in the muscle cells of many organs.
See kinnitub β2-retseptoritele, mida leidub paljude elundite lihasrakkudes.
It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways.
See seondub hingamisteede lihastes leiduvate β2- retseptoritega.
It works by blocking an enzyme called cyclo-oxygenase 2 (COX-2).
Toimeaine blokeerib ensüümi tsüklooksügenaas-2 (COX-2).
It works by blocking an enzyme called ‘DNA gyrase’, which is important in allowing bacteria to make copies of their DNA.
Selle toime seisneb ensüümi DNA-güraasi blokeerimises, mis on tähtis bakterite DNA replikatsioonil.
It works by blocking the bacterial enzyme RNA
See peatab bakteri Clostridium difficile kasvu ja paljunemise.
It works by blocking the bacterias’ ribosomes, the parts of the cell where proteins are produced, and blocking the growth of bacteria.
See blokeerib bakterite ribosoomid ehk rakuosad, kus toimub valgusüntees; ribosoomide blokeerimine pärsib bakterite kasvu.
It works by blocking the bacteria’s ribosomes (the parts of the cells where proteins are produced), inhibiting the growth of the bacteria.
Ravimi toime seisneb bakterite ribosoomide blokeerimises (need on raku osad, milles tekivad valgud) ja sellega pärsitakse bakterite kasvu.
It works by blocking the bacteria’s ribosomes, the parts of the cell where new proteins are made.
Tigetsükliin blokeerib bakterite ribosoome – raku osi, kus tekivad uued valgud.
It works by blocking the bacteria’s ribosomes, which are the parts of the cells where proteins are produced, and consequently inhibiting the growth of bacteria.
Selle toime seisneb bakterite ribosoomide (rakuosade, kus toimub valgusüntees) blokeerimises, millega pärsitakse bakterite kasvu.
It works by blocking the phosphodiesterase enzyme which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP).
Toimeaine blokeerib fosfodiesteraasi – ensüümi, mis tavaliselt lagundab tsüklilist guanosiinmonofosfaati (cGMP).
It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP).
Toimeaine blokeerib fosfodiesteraasi – ensüümi, mis tavaliselt lagundab tsüklilist guanosiinmonofosfaati (cGMP).
It works by blocking the production of proteins inside the bacteria and thereby stopping their growth.
See toimib, blokeerides valkude teket bakterites ja peatades sellega nende kasvu.
It works by blocking the receptors to which histamine, a substance in the body that causes allergic symptoms, normally attaches itself.
See blokeerib retseptoreid, mille külge histamiin – allergilisi sümptomeid põhjustav aine kehas – tavaliselt kinnitub.
It works by blocking ‘proton pumps’, proteins found in specialised cells in the stomach lining that pump acid into the stomach.
See blokeerib prootonpumbad, mao parietaalrakkudes leiduvad valgud, mis „pumpavad” makku hapet.
It works by blocking ‘proton pumps’, proteins found in specialised cells in the stomach lining, which pump acid into
Ravimi toimemehhanismiks on prootonipumpade (makku hapet „pumpavate” mao parietaalrakkudes leiduvate rakkude valkude)
It works by disrupting the formation of ergosterol, which is an important part of fungal cell membranes.
Selle toime seisneb seente rakumembraani olulise koostisaine ergosterooli moodustumise takistamises.
It works by disrupting the production of proteins that P. aeruginosa needs to build its cell walls, resulting in damage to the bacteria, which eventually kills them.
Ravim takistab P. aeruginosa rakuseinte ehitamiseks vajalike valkude tootmist, kahjustades sellega baktereid, mis lõpuks hävivad.
It works by entering cells and blocking the production of vascular endothelial growth factor (VEGF) and prostaglandins, substances that are involved in inflammation and swelling.
See toimib rakkudesse sisenedes ja blokeerides endoteeli kasvuteguri (VEGF) ning prostaglandiinide (põletikku ja turset põhjustavad ained) tekke.
It works by interfering with the formation of tube-like structures called ‘microtubules’ inside the cells of the worm that are needed to perform vital functions such as growth and cell division.
Fenbendasool takistab ussi rakkudes mikrotuubulite moodustumist, mis on vajalikud sellisteks elulisteks funktsioonideks nagu rakkude kasv ja jagunemine.
It works by interfering with the production of a component of the fungal cell wall called ‘glucan polysaccharide’, which is necessary for the fungus to continue living and growing.
Selle toime seisneb seene eluks ja kasvamiseks vajaliku rakuseinakomponendi glükaanpolüsahhariidi tekke takistamises.
It works by interfering with the production of a component of the fungal cell wall called ‘glucan polysaccharide’, which is necessary for the fungus to survive and grow.
Selle toime seisneb seene eluks ja kasvamiseks vajaliku rakumembraani komponendi glükaanpolüsahhariidi tootmise takistamises.
It works by preventing the release of the neurotransmitter noradrenaline from nerve cells in the body.
Neurotransmitterid on keemilised ained, mis vahendavad närvirakkude vahelisi signaale.
It works by reducing and preventing swelling and inflammation in your lungs and helps you to breathe more easily.
Ravim vähendab ja ennetab turset ja põletikku ja kergendab teie hingamist.
It works by replacing the missing factor IX to enable the patient’s blood to clot.
See asendab puuduva IX hüübimisfaktori, mis võimaldab patsientide verel hüübida.
It works by stopping certain particles in your blood (“platelets”) from sticking together to form blood clots which can block blood flow to important parts of your body including your heart and your brain.
See toimib, takistades teatud osakeste (trombotsüütide) kokkukleepumist veres ja verehüüvete teket, mis võivad sulgeda verevoolu teie tähtsatesse kehaosadesse, sh süda ja aju.
It works mainly by blocking an enzyme called cyclo-oxygenase-2 (COX- 2).
Ravimi toime põhineb peamiselt ensüümi tsüklooksügenaas-2 (COX-2) blokeerimisel.
It works mainly by blocking channels through which charged particles of potassium move in and out of the muscle cells.
Selle põhitoime avaldub lihasrakkudesse sisenevate ja sellest väljuvate kaaliumiioonide liikumist reguleerivate kanalite blokeerimises.
It works mainly by blocking the activity of ALK or ROS1, including when the genetic change is present, thereby reducing the growth and spread of the cancer in ALK-positive or in ROS1-positive NSCLC.
Xalkori toimib peamiselt ALK või ROS1 blokeerimise teel, ka geneetilise muutuse esinemisel, vähendades seeläbi ALK-positiivse või ROS1-positiivse mitte- väikerakulise kopsuvähi kasvu ja levikut.